Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

28 April 2016 : Original article  

Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation

Laetitia AlbanoABDE, Matthias BuchlerBDE, Diego CantarovichBDE, Elisabeth CassutoBDE, Olivier CointaultBDE, Hakim MazouzBDE, Fernando VetromileBDE, Aurélie LecuyerDE, Malka TindelCDE, Nassim KamarABDE

DOI: 10.12659/AOT.896213

Ann Transplant 2016; 21:250-261


BACKGROUND: Dosing of enteric-coated mycophenolate sodium (EC-MPS) should be adjusted to reflect concomitant immunosuppression, but it is largely undocumented whether such modifications are carried out during routine clinical practice.

MATERIAL AND METHODS: MyLIFE was an observational study of adult kidney-only or kidney-pancreas transplant patients starting ­EC-MPS at 33 French transplant centers. Data were collected at first EC-MPS dose and 6 months later. The primary objective was to describe initial EC-MPS dosing according to concomitant immunosuppression.

RESULTS: There were 461 patients analyzed (174 started EC-MPS by month 1 post-transplant [‘de novo’] and 287 started EC-MPS >1 month post-transplant [‘maintenance’]), receiving cyclosporine (CsA) (n=76), tacrolimus (n=363), or a mammalian target of rapamycin (mTOR) inhibitor (n=22). Mean (SD) starting dose was 1130 (511) mg/day, 1006 (441) mg/day, and 769 (300) mg/day in the CsA, tacrolimus, and mTOR inhibitor groups, respectively (p=0.003). In the de novo subpopulation, the starting dose was 1440 mg/day in 66.7% (14/21) of CsA-treated patients and 71.9% (110/153) of tacrolimus-treated patients, with an intensified dose of 2160 mg/day in 28.6% (6/21) and 8.5% (13/153), respectively. There was a non-significant trend to a higher rate of biopsy-proven acute rejection in patients receiving CsA versus tacrolimus or an mTOR inhibitor (p=0.082). Adverse events with a suspected relation to EC-MPS occurred in 21.0%, 23.1%, and 9.1% of the CsA, tacrolimus, and mTOR inhibitor subpopulations, respectively.

CONCLUSIONS: EC-MPS is usually initiated at the dose recommended for de novo CsA-treated kidney transplant patients, then titrated downwards as required. An early intensified regimen is not used frequently. The EC-MPS dose is modified in <20% of de novo patients to account for concomitant tacrolimus therapy instead of CsA administration.

Keywords: Cyclosporine, Kidney Transplantation, Mycophenolic Acid, Tacrolimus

Add Comment 0 Comments

699 8

In Press

17 May 2023 : Original article  

Results of Liver Retransplantation After Rescue Hepatectomy: A Single-Center Study

Ann Transplant In Press; DOI: 10.12659/AOT.939557  

10 May 2023 : Original article  

Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin ...

Ann Transplant In Press; DOI: 10.12659/AOT.939143  

Most Viewed Current Articles

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358